Oncoinvent (ONCIN)

[Merlin]

Ikke glem at Oncoin-aksjonærene har fått over 20% ekstra med aksjer i det nye selskapet, før emisjonen! Her er det altså flere “rabatter” å tenke på!

[Merlin]

• Byttet av Oncoinvent-aksjer mot BerGenBio-aksjer, vil ikke utløse skatteplikt i øyeblikket den gjennomføres. Opprinnelige inngangsverdi på aksjene videreføres til de nye aksjene.
• Privatpersoner: Du skatter først på gevinsten når du selger aksjene.
• Selskaper: For aksjeselskap gjelder fritaksmetoden, noe som betyr at aksjegevinsten er skattefri.
• Aksjesparekonto (ASK): Aksjebyttet skjer skattefritt inne på kontoen. Du betaler skatt på gevinst først når du tar ut penger som overstiger det opprinnelige innskuddet.
• Overgang til hovedlisten: Overføringen fra Euronext Growth til hovedlisten har ingen skattemessige konsekvenser i seg selv. Men, aksjer på hovedlisten inngår i formueskatten for personlige aksjonærer, noe som aksjer på Euronext Growth ikke gjør. (BerGenBio er imidlertid allerede notert på hovedlisten.)

[Merlin]

Kan radspherin erstatte BCG ved blærekreft?

Som kjent anvendes BCG som standard sluttbehandling etter TURB-T. TURB-T er den vanligste første kirurgiske behandlingen for overfladisk blærekreft (ikke-muskelinvasiv blærekreft), og kan i mange tilfeller være tilstrekkelig for å fjerne all kreft.

BCG har en rekke bivirkninger og behandlingen gjentas 6 ganger. Allikevel er effekten bare ca 50%.

Radspherin bør kunne gi mye bedre effekt og kun etter én gangs bruk for å fjerne mikrometastaser

• BCG-refraktær kreft: En betydelig andel pasienter, spesielt de med høyrisikokreft, reagerer ikke på BCG-behandlingen i det hele tatt, eller kreften kommer tilbake kort tid etter behandling. Dette kalles “BCG-refraktær” kreft. For disse pasientene er det en stor utfordring, og de må ofte vurdere mer radikal kirurgi, som å fjerne hele blæren (cystektomi).

I EU +USA opereres rundt 160 000 pasienter årlig med blærekreft. Over 30 000 av disse må fjerne urinblæren ien omfattende og vanskelig operasjon. Radspherin kunne vært en gamechanger for disse pasientene.

[HBA]

Bytteforholdet er definert til at ONCOIN aksjonærene skal eie 75% av selskapet ved merger og BGBIO aksjonærer de resterende 25% av selskapet. Total fordeling før emisjon. Så derfor mottar vi ca 1,2 BGBIO aksje for hver ONCOIN. Så det er ikke slik at vi mottar 20% ekstra av selskapets totale antall aksjer ved merger.

[Merlin]

Jeg snakker om hva du får tegningsrett til, i forhold til det antall aksjer du har i Oncoin i dag. Og det økes med over 20% I antall.

Ellers en grei presisering som vel de fleste kjenner til.

[HBA]

Noen som vet hvorfor Radforsk inv. stift. har solgt seg ned/ ut av topp 50 nå i år? Jonas E. har jo vært veldig optimitisk med tanke på fremtiden for selskapet.

[Boms]

Jeg tipper at de rett og slett trenger penger. De ble jo “tvangssolgt” i Nykode i fjor.

[Merlin]

Sum egenkapital i mill kr. pr 31/12
311 2020
289 2021
879 2022
697 2023
81 2024

Radforsk tapte over 600 mill kr. i 2024 og EK er nesten vekk. Ser ut som om de selger unna alt som har likviditet, uten hensyn til fremtidsvurderinger.

[HBA]

De solgt vel mye NYKD når ULTI kollapset.
I den forbindelse varslet de ikke behov for å selge mere, eller i andre selskaper.
Men, kapitalbehovet kan ha blitt endret.
Håper de solgte ONCOIN for å bedre likviditet, men fortsatt har tro på teknologien.

[HBA]

Er vel ikke mye butikk å kjøpe ONCOIN aksjer på 1,50 ++ når det er mulig å kjøpe BGBIO aksjer på 1,10. Bytteforholdet er 1,20268 BGBIO aksje for hver ONCIN-aksje.
Dvs: Ved merge er ONCOIN aksjene med dagens BGBIO kurs ca 1,32.
Så skal vel kursen på BGBIO aksjen kjøres ytterligere ned etter merger for å få lavest emisjonskurs.
Må håpe på en kraftig kursøkning etter at emisjonen er gjennomført bare for å nå “break even” da…

[TekBot]

Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue

Oslo, 17 September 2025: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 5 August 2025 regarding updated
key information relating to the contemplated fully underwritten rights issue in
…

Vis børsmeldingen

the Company raising gross proceeds of NOK 130 million (the “Rights Issue”).
Reference is also made to the stock exchange announcement made by the Company
earlier today on 17 September 2025, with updated information regarding the
timeline for the Rights Issue and the contemplated combination of the Company,
Oncoinvent and BerGenBio Norge AS through a statutory triangular merger (the
“Merger”). Updated key information relating to the Rights Issue is set out
below.

Date on which the terms and conditions of the preferential rights issue were
announced: 30 June 2025.

Last day including rights: 11 November 2025.

Ex-date: 12 November 2025.

Record Date: 13 November 2025 (assuming normal T+2 settlement).

Date of approval: 4 August 2025.

Maximum number of new shares: To be announced when the subscription price has
been determined.

Subscription price: The subscription price in the Rights Issue will be set
following close of trading on Euronext Oslo Børs on the 9th trading date after
completion of the Merger (the “Pricing Date”) and be equal to the theoretical
share price exclusive of the subscription rights (TERP), calculated on the basis
of the volume weighted average price (VWAP) quoted for the shares in the Company
the last three trading days leading up to and including the Pricing Date, less a
discount of approx. 35%, however such that the subscription price shall not be
lower than the minimum nominal value that can be set if a share capital
reduction shall be implemented without a creditor notification.

Ratio preferential rights: To be announced when the maximum number of new shares
in the Rights Issue has been determined.

Subscription ratio: 1:1 (number of new shares in the combined company following
the Merger per subscription right).

Global Coordinators: ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank
ASA (the “Managers”).

Will the rights be listed: Yes, the combined company will apply for listing of
the subscription rights on the Euronext Oslo Børs.

ISIN for the preferential rights: To be announced when available.

Other information: Reference is made to the stock exchange announcements
published by the Company on 30 June 2025 for further information regarding the
Rights Issue and the Merger. The Rights Issue is subject to, inter alia, (i)
completion of the Merger and (ii) publication of a prospectus for offering and
listing of the new shares as approved by the Norwegian Financial Supervisory
Authority, expected to take place on or about 28 October 2025.

For further information, please contact:

Øystein Soug, CEO, Oncoinvent ASA, soug@oncoinvent.com

Tore Kvam, CFO, Oncoinvent ASA, kvam@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

IMPORTANT INFORMATION

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company or Oncoinvent in
the United States or any other jurisdiction. Copies of this document may not be
sent to jurisdictions, or distributed in or sent from jurisdictions, in which
this is barred or prohibited by law. The securities of the Company and
Oncoinvent may not be offered or sold in the United States absent registration
or an exemption from registration under the U.S. Securities Act of 1933, as
amended (the “U.S. Securities Act”).

The securities of the Company and Oncoinvent have not been, and will not be,
registered under the U.S. Securities Act. Any sale in the United States of the
securities mentioned in this communication will be made solely to “qualified
institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No
public offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made by
means of the Prospectus. This announcement is an advertisement and is not a
prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a regulated
market, and repealing Directive 2003/71/EC (as amended) as implemented in any
EEA Member State (the “Prospectus Regulation”). Investors should not subscribe
for any securities referred to in this announcement except on the basis of
information contained in the Prospectus. Copies of the Prospectus will,
following publication, be available from the Company’s registered office and,
subject to certain exceptions, on the website of the Managers.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, the United States or any other jurisdiction in which
such release, publication or distribution would be unlawful, and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States or to publications with a general circulation in the
United States of America.

The Managers are acting for the merged Company in connection with the Rights
Issue and no one else and will not be responsible to anyone other than the
merged Company for providing the protections afforded to their respective
clients or for providing advice in relation to the Rights Issue or any
transaction or arrangement referred to in this announcement. Matters discussed
in this announcement may constitute forward-looking statements. Forward-looking
statements are statements that are not historical facts and may be identified by
words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”,
“intends”, “may”, “should”, “will” and similar expressions. The forward-looking
statements in this release are based upon various assumptions, many of which are
based, in turn, upon further assumptions.

Although the Company and Oncoinvent believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its control.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The information, opinions and
forward-looking statements contained in this announcement speak only as at its
date and are subject to change without notice. This announcement is made by and
is the responsibility of, the Company. Neither the Managers nor any of their
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company or Oncoinvent. No
reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness or completeness. Neither the Managers nor
any of their respective affiliates accepts any liability arising from the use of
this announcemen

Kilde

[TekBot]

Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and Merger

Oslo, 17 September 2025: Reference is made to the joint stock exchange
announcement made on 30 June 2025 by BerGenBio ASA (the “Company”) and
Oncoinvent ASA (“Oncoinvent”) regarding the contemplated combination of the
…

Vis børsmeldingen

Company, Oncoinvent and BerGenBio Norge AS through a statutory triangular merger
(the “Merger”). Reference is also made to the stock exchange announcement made
by the Company on 30 June 2025 regarding a fully underwritten rights issue (the
“Rights Issue”) with preferential subscription rights (the “Subscription
Rights”) for the Company’s existing shareholders at the time of completion of
the Merger (the “Rights Issue Announcement”).

As mentioned in the Rights Issue Announcement, the Company will prepare and
publish an EEA prospectus for, inter alia, the offering and listing of the
shares to be issued in the Rights Issue (the “Offer Shares”) and for the listing
of the consideration shares to be issued in the Merger (the “Merger Shares”).
The prospectus will include the full terms and conditions of the Rights Issue
and will be subject to approval by the Norwegian Financial Supervisory Authority
prior to publication (the “Prospectus”). Due to delays in the Prospectus work
stream, the key dates previously announced by the Company and Oncoinvent in
connection with the Rights Issue have changed.

The first draft of the Prospectus has been submitted to the Norwegian Financial
Supervisory Authority. It is expected that the Prospectus will be approved on or
about 28 October 2025. Furthermore, the Company and Oncoinvent expect that the
Merger will be completed on or about 29 October 2025, with the first day of
trading in the shares of the combined Company expected on or about 30 October
2025. Euronext Oslo Børs has approved that conditions for the continued listing
of the Company’s shares on Euronext Oslo Børs after completion of the Merger are
met. The subscription period for the Rights Issue is expected to commence on or
about 14 November 2025 at 09:00 hours CET and expire at 16:30 hours CET on 28
November 2025. Delivery of the Offer Shares is expected to take place on or
about 8 December 2025, through the facilities of the Norwegian Central
Securities Depository.

For further information regarding the Rights Issue, reference is made to the
Rights Issue Announcement. For further information regarding the Merger and the
complete terms and conditions for the Merger, reference is made to the merger
plan with appendices available on www.bergenbio.no.

For further information, please contact:

Øystein Soug, CEO, Oncoinvent ASA, soug@oncoinvent.com

Tore Kvam, CFO, Oncoinvent ASA, kvam@oncoinvent.com (kvam@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Merlin]

First day of trading in the shares of the combined Company expected on or about 30 October
2025.

Da skal aksjonærene i Oncoin på forhånd ha fått øket sitt aksjeantall med ca 20%.

The subscription period for the Rights Issue is expected to commence on or
about 14 November 2025 at 09:00 hours CET and expire at 16:30 hours CET on 28
November 2025. Delivery of the Offer Shares is expected to take place on or
about 8 December 2025,

Dagens kurser i selskapene er helt hopp og sprett. Når aksjen endelig er børsnotert og og den garanterte emisjonen på 130 mill kr er gjennomført bør vi få en normalisering, som igjen er avhengig av at selskapet klarer å holde tempoet oppe i inklusjonsantallet.

[HBA]

Først skulle de merge i september, så oktober, hva blir endelig resultat, tre ganger nå de har endret dato for ex TR. Somler de bevisst, eller har de noe de ønsker (håper på) å melde markedet som kan bidra til høyere kurs i de 9 dagene som vil avgjøre tegnigskurs på dag 10.

Det kan jo ikke komme som en overraskelse av selskapet trenger et prospekt etc. Eller er hele ledelsen i begge selkaper så fjernstyrte at de ikke aner hva de egentlige driver med…

[InVivo]

@HBA

de noe de ønsker (håper på) å melde markedet som kan bidra til høyere kurs i de 9 dagene som vil avgjøre tegnigskurs på dag 10.

De største eierne er likegyldig til aksjekursen, så det tviler jeg på.

[HBA]

Blir vel litt forenklet å regne på denne måten med kun se på antall aksjer mener jeg (så kan det være mulig jeg har oversett noe).
I dag eier aksjonærene i ONCOIN 100% av selskapet.
Etter merge eier ONCOIN aksjonærene 75% og BGBIO aksjonærene 25% av det sammenslåtte selskapet. Så de ca 20% er kun for å få eierbrøk til å gå opp ifht 75% vs 25% eierskap i det nye selskapet.

Ja, du har feks 10 000 aksjer i dag, og mottar ca 12 000 aksjer i det nye selskapet.
Men, det jo da mange flere aksjer som utgjør 100% eierskap.

En annen ting.
Gml. ONCOIN aksjonærene vil motta 75% av totalt antall TR som utstedes, ikke 100% av totalt antall TR.

[Merlin]

Ja man må se på helheten. Flere aksjer, lavere eierandel, men også en innbetaling av midlene i BGBIO.

[emitl]

Dette er langt frem i tid. Jeg synes det ser veldig skummelt ut kursmessig med 35% rabatt på en emisjon som ikke kommer før 11. november. Det er veldig mange dager å falle på:

Siste dag inklusiv rettigheter er 11. november. Tegningskursen vil bli satt etter ni handelsdager på Oslo Børs etter fullføring av fusjonen mellom BerGenBio, Oncoinvent og BerGenBio Norge, basert på en teoretisk kurs (TERP) med en rabatt på om lag 35 prosent.

[the1nonly]

@emitl

emisjon som ikke kommer før 11. november

Nå følger jeg ikke denne dag til dag. Men hvorfor er emi flyttet til senere tidspunkt en opprinnelig planlagt? Er nok sene tidslinjer i utgangspunktet om ikke en planlagt emi også skal gå i skilpadde tempo.

[InVivo]

@the1nonly

Er nok sene tidslinjer i utgangspunktet om ikke en planlagt emi også skal gå i skilpadde tempo.

Spiller det egentlig noen rolle all den tid emisjonsbeløpet er garantert for?